Literature DB >> 12499051

Alteration of 8-hydroxyguanosine concentrations in the cerebrospinal fluid and serum from patients with Parkinson's disease.

Takashi Abe1, Chiaki Isobe, Takahiko Murata, Chigumi Sato, Hideo Tohgi.   

Abstract

In order to investigate the possible role of oxidative RNA damage in the pathogenesis of Parkinson's disease (PD), the concentrations of the oxidative stress marker 8-hydroxyguanosine (8-OHG) were measured in the cerebrospinal fluid (CSF) and the serum of patients with PD and control subjects. The concentration of 8-OHG in CSF in PD patients was approximately three-fold that in controls (P < 0.001). The concentration of 8-OHG in CSF decreased significantly with the duration of disease (r(s) = -0.46, P < 0.05). However, the concentration of 8-OHG in serum was not significantly altered in PD patients compared to that in controls. In addition, the concentration of 8-OHG in CSF showed no correlation with that in serum in both the controls and PD patients suggesting that the 8-OHG concentrations in the CSF do not reflect those in serum and may be probably reflect those in brain tissue. These in vivo findings suggest a possible role of 8-OHG and increased oxidative RNA damage in the early stage of the development of PD. Copyright 2002 Elsevier Science Ireland Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12499051     DOI: 10.1016/s0304-3940(02)01259-4

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  27 in total

Review 1.  Oxidative damage to RNA in aging and neurodegenerative disorders.

Authors:  Akihiko Nunomura; Paula I Moreira; Rudy J Castellani; Hyoung-Gon Lee; Xiongwei Zhu; Mark A Smith; George Perry
Journal:  Neurotox Res       Date:  2012-06-06       Impact factor: 3.911

Review 2.  Current perspectives on the clinical implications of oxidative RNA damage in aging research: challenges and opportunities.

Authors:  Zhijie Xu; Jinzhou Huang; Ming Gao; Guijie Guo; Shuangshuang Zeng; Xi Chen; Xiang Wang; Zhicheng Gong; Yuanliang Yan
Journal:  Geroscience       Date:  2020-06-11       Impact factor: 7.713

3.  Neuroinflammation, Oxidative Stress and the Pathogenesis of Parkinson's Disease.

Authors:  R Lee Mosley; Eric J Benner; Irena Kadiu; Mark Thomas; Michael D Boska; Khader Hasan; Chad Laurie; Howard E Gendelman
Journal:  Clin Neurosci Res       Date:  2006-12-06

Review 4.  Blood-based protein biomarkers for diagnosis and classification of neurodegenerative diseases: current progress and clinical potential.

Authors:  Carmen Noelker; Harald Hampel; Richard Dodel
Journal:  Mol Diagn Ther       Date:  2011-04-01       Impact factor: 4.074

Review 5.  Oxidative damage to macromolecules in human Parkinson disease and the rotenone model.

Authors:  Laurie H Sanders; J Timothy Greenamyre
Journal:  Free Radic Biol Med       Date:  2013-01-15       Impact factor: 7.376

Review 6.  Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance.

Authors:  Chun Zhou; Yong Huang; Serge Przedborski
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

Review 7.  Markers of oxidant stress that are clinically relevant in aging and age-related disease.

Authors:  Kimberly D Jacob; Nicole Noren Hooten; Andrzej R Trzeciak; Michele K Evans
Journal:  Mech Ageing Dev       Date:  2013-02-18       Impact factor: 5.432

8.  Do mtDNA Mutations Participate in the Pathogenesis of Sporadic Parkinson's Disease?

Authors:  E Kirches
Journal:  Curr Genomics       Date:  2009-12       Impact factor: 2.236

9.  Sublethal RNA oxidation as a mechanism for neurodegenerative disease.

Authors:  Rudy J Castellani; Akihiko Nunomura; Raj K Rolston; Paula I Moreira; Atsushi Takeda; George Perry; Mark A Smith
Journal:  Int J Mol Sci       Date:  2008-05-20       Impact factor: 6.208

10.  Prodromal non-motor symptoms of Parkinson's disease.

Authors:  Clelia Pellicano; Dario Benincasa; Vincenzo Pisani; Francesca R Buttarelli; Morena Giovannelli; Francesco E Pontieri
Journal:  Neuropsychiatr Dis Treat       Date:  2007-02       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.